Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trospium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.97 |
| ▸ | HRH1 | P35367 | 3/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trospium SCHEMBL13836646 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL29389006 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL29629492 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL25785 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL119810 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL2447242 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL724191 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL31112961 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL22609933 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL1707994 | 0.94 | CHRM3 (0.89) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-3436186-B1 | POLY(ARYL PIPERIDINIUM) POLYMERS FOR USE AS HYDROXIDE EXCHANGE MEMBRANES AND IONOMERS | UNIV DELAWARE (US) | 2025-07-16 | — | — | EP | claimed |
| CN-118318002-A | Antioxidant polymers for use as anion exchange membranes and ionomers | 特拉华大学 | 2024-07-09 | — | — | CN | claimed |
| US-20240131477-A1 | OXIDATION RESISTANT POLYMERS FOR USE AS ANION EXCHANGE MEMBRANES AND IONOMERS | UNITED STATES DEPARTMENT OF ENERGY | 2024-04-25 | — | — | US | claimed |
| EP-4314142-A1 | OXIDATION RESISTANT POLYMERS FOR USE AS ANION EXCHANGE MEMBRANES AND IONOMERS | University of Delaware (US) | 2024-02-07 | — | — | EP | claimed |
| US-11512156-B2 | Poly(aryl piperidinium) polymers including those with stable cationic pendant groups for use as anion exchange membranes and ionomers | UNIVERSITY OF DELAWARE (US) | 2022-11-29 | — | — | US | claimed |
| EP-4088717-A1 | USE AND COMPOSITION FOR TREATING DEMENTIA | Chase Pharmaceuticals Corporation (US) | 2022-11-16 | — | — | EP | claimed |
| WO-2022170022-A1 | OXIDATION RESISTANT POLYMERS FOR USE AS ANION EXCHANGE MEMBRANES AND IONOMERS | UNIVERSITY OF DELAWARE (US) | 2022-08-11 | — | — | WO | claimed |
| CN-104739808-B | Double release capsules of a kind of trospium chloride and preparation method thereof | 舒泰神（北京）生物制药股份有限公司 | 2017-09-22 | — | — | CN | claimed |
| CN-104739808-A | Trospium chloride double-release capsules and preparation method thereof | STAIDSON BEIJING BIOPHARMACEUTICALS CO LTD | 2015-07-01 | — | — | CN | claimed |
| CN-102718760-B | Trospium chloride synthesis process | Shouguang fukang pharmaceutical co ltd | 2014-07-02 | — | — | CN | claimed |
| CN-103690506-A | Trospium chloride slow-release composition and preparation method thereof | STAIDSON BEIJING BIOPHARMACEUTICALS CO LTD | 2014-04-02 | — | — | CN | claimed |
| CN-102718760-A | Trospium chloride synthesis process | Shouguang fukang pharmaceutical co ltd | 2012-10-10 | — | — | CN | claimed |
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12616964-B2 | Spirocyclic compound containing catalyst for use in catalyzing reaction of epoxide compound and carbon dioxide | SHENZHEN CAPCHEM TECHNOLOGY CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4727992-A1 | AEM ROLL-TO-ROLL INK FORMULATIONS AND PROCESSES FOR CO2 ELECTROLYZERS | Twelve Benefit Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2006000398-A1 | 2,3-BENZOXAZIN DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005005451-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005452-A1 | SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| EP-1072260-A1 | Transdermal systems for the release of muscarinic receptor antagonists and use thereof for treatement of smooth muscle spasms in urology | Novosis Pharma AG (DE) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616964-B2 | Spirocyclic compound containing catalyst for use in catalyzing reaction of epoxide compound and carbon dioxide | RCC2, NR3C2, CA2 | CHRM3 3288/4885CHRM2 1844/4885CHRM1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.